Takeda Pharmaceutical Co. Ltd.

History

Year	Detail
1781	The esteemed lineage of Takeda Pharmaceutical Co. Ltd. commenced with the entrepreneurial venture of Chobei I, who initiated the trade of traditional Japanese and Chinese herbal medicines in Doshomachi, Osaka, Japan.
1871	Takeda embarked on an epoch of global engagement by establishing a cooperative union in Yokohama for the procurement of Western medicines, marking the inception of its interactions with foreign trading entities.
1895	Consolidating its commitment to excellence, Takeda acquired Uchibayashi Drug Works, thus establishing its own manufacturing facility in Osaka.
1914	A dedicated research division was instituted, signaling Takeda's foresight into the significance of scientific inquiry within pharmaceutical development.
1915	Takeda Pharmaceutical Company was formally established, solidifying its foundation as a prominent entity within the pharmaceutical landscape.
1925	Reflecting its expanding stature, the company was formally incorporated as Chobei Takeda & Co., Ltd., underlining its enduring legacy.
1933	Takeda underscored its dedication to botanical preservation with the establishment of the Takeda Garden for Medicinal Plant Conservation, a testament to its reverence for nature's contributions to medicinal science.
1944	The Institute for Fermentation was inaugurated in Osaka, amplifying Takeda's commitment to pioneering research methodologies.
1946	The inauguration of the Hikari Plant marked a significant milestone in Takeda's manufacturing capabilities, underscoring its commitment to ensuring the highest standards of production.
1950	Takeda achieved a landmark by introducing Panvitan, Japan's premier multivitamin, exemplifying its dedication to innovation in healthcare.
1953	Takeda's global footprint expanded with the establishment of Lederle (Japan) Ltd., a strategic joint venture aimed at enhancing its international presence.
1960	The establishment of the Shoshisha Foundation furthered Takeda's commitment to societal welfare, exemplifying its ethos of corporate responsibility.
1962	Takeda's global outreach extended to Southeast Asia with the establishment of manufacturing and marketing entities, laying the groundwork for future growth and collaboration.
1963	The establishment of the Takeda Science Foundation underscored the company's commitment to fostering scientific advancement and scholarship.
1978	Takeda's global expansion continued with the establishment of a pharmaceutical marketing joint venture in France, solidifying its presence in key international markets.
1985	A transformative collaboration ensued with the formation of TAP Pharmaceuticals Inc. in the U.S., a pivotal joint venture with Abbott Laboratories aimed at synergistic innovation.
1988	The establishment of the Tsukuba Research Laboratories marked a significant stride in Takeda's research capabilities, heralding an era of groundbreaking scientific discovery.
1989	Takeda's legacy of innovation continued with the successful launch of Lupron Depot, a testament to its unwavering pursuit of medical breakthroughs.
1995	LI Takeda Ltd. was established as a specialized subsidiary, furthering Takeda's commitment to diversification and specialization within its operational framework.
1997	Takeda's global research footprint expanded with the establishment of Takeda America Research & Development Center Inc., underscoring its dedication to cutting-edge research.
1998	The establishment of Takeda Europe Research & Development Centre Ltd. in the U.K. marked a pivotal step in bolstering Takeda's research capabilities on the international stage.
2005	Takeda augmented its research endeavors with the integration of Syrrx, Inc., a prominent U.S. bio-venture, into its global research and development network.
2007	A strategic integration unfolded with the incorporation of Paradigm Therapeutics Limited, enriching Takeda's research portfolio with diverse expertise and capabilities.
2009	Dexilant's successful launch in the U.S. underscored Takeda's commitment to delivering innovative therapeutic solutions to address unmet medical needs.
2012	Takeda fortified its commitment to public health with the establishment of its Global Vaccine Business, aimed at advancing preventive healthcare initiatives worldwide.
2019	Takeda reached a transformative milestone with the completion of its acquisition of Shire plc, marking a significant expansion of its global footprint and therapeutic portfolio.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.